An interesting article in Time magazine highlights the economics that can contribute to fragile medicine supply chains. Price pressures from purchasers without guaranteed volumes can result in generic manufacturers switching to produce more profitable lines. There may also be insufficient manufacturers to cover supply if an individual plant goes offline.

Read more here.